$LBRX News
Last published 3d ago
- 3d agoLBRXLB Pharmaceuticals Inc (LBRX) Guggenheim 3rd Annual Healthcare Innovation Conference - LB PHARMACEUTICALS INCEarnings Call Transcriptshealthcare innovation conference. I am Delma Cagliatti and I'm one of the analysts here at Guggenheim and it's my pleasure to welcome next LB Pharma here with us. So from the company we have Gad Soffer, the chief operati
- 1w agoLBRXLB PHARMACEUTICALS INC - EX-99.1Earnings ReleasesForm 8-K - Current report - Item 2.02 Item 9.01
- 1w agoLBRXLB Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Corporate UpdateGlobeNewswireStrengthened leadership with the appointment of Susan G. Kozauer, M.D., as Chief Medical Officer and Joseph Miller as Chief Financial Officer On track for topline data readout from the pivotal Phase 3 NOVA-2 trial of
- 1w agoLBRXLB Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Corporate UpdateGlobeNewswireStrengthened leadership with the appointment of Susan G. Kozauer, M.D., as Chief Medical Officer and Joseph Miller as Chief Financial Officer On track for...
- 3w agoLBRXLB Pharmaceuticals (LBRX) Fireside Chat - LB PHARMACEUTICALS INCEarnings Call TranscriptsThank you, everyone, for tuning into today's Biotech Catalyst Conference here at Craig Hallam. My name is Adam Vogel. I'm a biotech analyst at Craig Hallam, and today we have with us from LB Pharma, CEO Heather Turner. H
- 4w agoLBRXLB Pharmaceuticals to Participate in Upcoming Investor EventsGlobeNewswireNEW YORK, Oct. 15, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc ("LB Pharmaceuticals" or the "Company") (NASDAQ:LBRX), a neuromedicines company dedicated to developing and commercializing
- 1mo agoLBRXLB Pharmaceuticals Presents New Preclinical Data Supporting LB-102’s Bimodal Mechanism of Action and Highlights Ongoing Late-Stage Clinical Development Programs at the 39th ECNP CongressGlobeNewswireNEW YORK, Oct. 10, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc ("LB Pharmaceuticals" or the "Company") (NASDAQ:LBRX), a neuromedicines company dedicated to developing and commercializing
- 1mo agoLBRXLB Pharmaceuticals Reports Inducement Grants to New Employee Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireNEW YORK, Oct. 09, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc ("LB Pharmaceuticals" or the "Company") (NASDAQ:LBRX), a neuromedicines company dedicated to developing and commercializing
- 1mo agoLBRXTD Cowen 6th Annual Novel Mechanisms in Neuropsychiatry Summit - LB PHARMACEUTICALS INCEarnings Call TranscriptsGood afternoon, everyone. Thanks for joining us for the final afternoon stretch of the sixth annual Novel Mechanisms of Neuropsychiatry Summit hosted by T.D. Cowan. And welcome to the Fireside Chat with LB Pharmaceutical
- 1mo agoLBRXLB Pharmaceuticals Appoints Susan G. Kozauer, M.D. as Chief Medical OfficerGlobeNewswireNEW YORK, Sept. 15, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc ("LB Pharmaceuticals" or the "Company") (NASDAQ:LBRX), a neuromedicines company dedicated to developing and commercializing
- 2mo agoLBRXLB Pharmaceuticals to Participate in Upcoming September Investor EventsGlobeNewswireNEW YORK, Sept. 03, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc ("LB Pharmaceuticals" or the "Company") (NASDAQ:LBRX), a neuromedicines company dedicated to developing and commercializing
- 2mo agoLBRXLB Pharmaceuticals Appoints Joseph Miller as Chief Financial OfficerGlobeNewswireNEW YORK, Sept. 03, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc ("LB Pharmaceuticals" or the "Company") (NASDAQ:LBRX), a neuromedicines company dedicated to developing and commercializing
- 3mo agoLBRXLB Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Corporate UpdateGlobeNewswireAnnounced accelerated timing of topline data readout from the pivotal Phase 3 NOVA-2 trial of LB-102 in schizophrenia in the first half of 2027 Announced plans for pipeline expansion of LB-102 into new neuropsychiatric
- 3mo agoLBRXLB Pharmaceuticals Announces $150 Million Private PlacementGlobeNewswireNEW YORK, July 29, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc ("LB Pharmaceuticals" or the "Company") (NASDAQ:LBRX), a neuromedicines company dedicated to developing and commercializing
- 3mo agoLBRXLB Pharmaceuticals Announces Accelerated Timing of Topline Results from the Phase 3 NOVA-2 Trial of LB-102 in SchizophreniaGlobeNewswireNEW YORK, July 22, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc ("LB Pharmaceuticals" or the "Company") (NASDAQ:LBRX), a neuromedicines company dedicated to developing and commercializing
- 4mo agoLBRXLB Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireNEW YORK, July 10, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc ("LB Pharmaceuticals" or the "Company") (NASDAQ:LBRX), today announced that it has granted to Christopher Zergebel, the new Senior
- 4mo agoLBRXLB Pharmaceuticals Appoints Christopher Zergebel as Senior Vice President, Clinical OperationsGlobeNewswireNEW YORK, June 30, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc ("LB Pharmaceuticals" or the "Company") (NASDAQ:LBRX), a late-stage biopharmaceutical company developing novel therapies for
- 5mo agoLBRXLB Pharmaceuticals to Participate in Upcoming June Investor EventsGlobeNewswireNEW YORK, May 28, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc ("LB Pharmaceuticals" or the "Company") (NASDAQ:LBRX), a late-stage biopharmaceutical company developing novel therapies for schizophrenia, bipolar
- 6mo agoLBRXLB Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Corporate UpdateGlobeNewswireInitiated two late-stage clinical trials of LB-102: the pivotal Phase 3 NOVA-2 trial in schizophrenia and the Phase 2 ILLUMINATE-1 trial in bipolar depression Published results from the Phase 2 NOVA-1 trial of LB-102
- 6mo agoLBRXLB Pharmaceuticals Announces Publication in JAMA Psychiatry of Results from Phase 2 NOVA-1 Trial of LB-102 in SchizophreniaGlobeNewswirePivotal Phase 3 NOVA-2 trial in schizophrenia ongoing, topline data expected in 2H 2027LB-102 has potential to be the first benzamide approved for schizophrenia in the U.S. NEW YORK, April 22, 2026 (GLOBE NEWSWIRE) --
- 7mo agoLBRXLB Pharmaceuticals Announces Presentation at 25th Annual Needham Virtual Healthcare ConferenceGlobeNewswireNEW YORK, April 09, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc ("LB Pharmaceuticals" or the "Company") (NASDAQ:LBRX), a late-stage biopharmaceutical company developing novel therapies for schizophrenia, bipolar
- 7mo agoLBRXLB Pharmaceuticals Presents New Analysis from the Phase 2 NOVA-1 Trial Highlighting LB-102's Potential Impact on Cognitive Performance at the 2026 Annual Congress of the Schizophrenia International Research Society (SIRS)GlobeNewswireNEW YORK, March 27, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc ("LB Pharmaceuticals" or the "Company") (NASDAQ:LBRX), a late-stage biopharmaceutical company developing novel therapies for schizophrenia, bipolar
- 7mo agoLBRXLB Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate UpdateGlobeNewswireReported positive results from potentially registrational Phase 2 trial ofLB-102 in schizophrenia Advanced LB-102 into late-stage development in multiple indications with initiation ofa pivotal Phase 3 NOVA-2 trial in
- 7mo agoLBRXLB Pharmaceuticals Initiates Pivotal Phase 3 Trial (NOVA-2) for LB-102 in Patients with SchizophreniaGlobeNewswireLB-102 has potential to be the first benzamide approved for schizophrenia in the U.S. NOVA-2 trial to enroll approximately 460 patients Primary endpoint to evaluate change in PANSS total score at week 6; secondary
- 8mo agoLBRXSTIFEL 2026 VIRTUAL CNS FORUM - LB PHARMACEUTICALS INCEarnings Call Transcriptsuh great thanks very much everybody it's my pleasure to be moderating this chat with heather turner ceo of lb pharma um we'll keep this mostly conversational but maybe heather to start you could give us a two to three mi
- 8mo agoLBRXLB Pharmaceuticals Appoints R&D Biotech Executive Robert Lenz, M.D., Ph.D. to Board of DirectorsGlobeNewswireNEW YORK, March 09, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc ("LB Pharmaceuticals" or the "Company") (NASDAQ:LBRX), a late-stage biopharmaceutical company developing novel therapies for schizophrenia, bipolar
- 8mo agoLBRXLB Pharmaceuticals to Participate in Upcoming March Investor EventsGlobeNewswireNEW YORK, March 04, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc ("LB Pharmaceuticals" or the "Company") (NASDAQ:LBRX), a late-stage biopharmaceutical company developing novel therapies for schizophrenia, bipolar
- 8mo agoHELPATAIDFTXGHRS+1Psychedelic Biotechs Push Toward Phase 3: Five Companies Advancing CNS TreatmentsPR NewswireEquity-Insider.com News Commentary — Psychedelic compounds are edging closer to regulatory approval as pivotal trials in treatment-resistant...
- 9mo agoLBRXLB Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireNEW YORK, Feb. 10, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc ("LB Pharmaceuticals" or the "Company") (NASDAQ:LBRX) today announced that it has granted to Dr. Minako Pazdera, the new General Counsel of LB
- 9mo agoLBRXLB Pharmaceuticals Announces $100.0 Million Private PlacementGlobeNewswireNEW YORK, Feb. 05, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc ("LB Pharmaceuticals" or the "Company") (NASDAQ:LBRX), a late-stage biopharmaceutical company developing novel therapies for schizophrenia, bipolar
- 9mo agoLBRXLB Pharmaceuticals Initiates Phase 2 ILLUMINATE-1 Trial in Bipolar Depression, Expanding LB-102 Development ProgramGlobeNewswireTopline data expected in 1Q 2028 Phase 2 bipolar depression trial initiation follows positive Phase 2 results in acute schizophrenia NEW YORK, Jan. 26, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc ("LB
- 9mo agoLBRXLB Pharmaceuticals Appoints Minako Pazdera, J.D., Ph.D. as General CounselGlobeNewswireNEW YORK, Jan. 21, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals, Inc ("LB Pharmaceuticals" or the "Company") (NASDAQ:LBRX), a clinical-stage biopharmaceutical company developing novel therapies for schizophrenia,
- 10mo agoLBRXLB Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireNEW YORK, Jan. 12, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc ("LB Pharmaceuticals" or the "Company") (NASDAQ:LBRX) today announced that it has granted to Ellen Rose, the new Senior Vice President, Corporate
- 11mo agoLBRXLB Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireNEW YORK, Dec. 10, 2025 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc ("LB Pharmaceuticals" or the "Company") (NASDAQ:LBRX) today announced that it has granted to Kaya Pai Panandiker, the new Chief Commercial Officer of
- 11mo agoLBRXLB Pharmaceuticals Added to the Russell 2000® and Russell 3000® IndicesGlobeNewswireNEW YORK, Dec. 09, 2025 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc ("LB Pharmaceuticals" or the "Company") (NASDAQ:LBRX) today announced the Company has been included in the Russell 2000® Index and the
- 11mo agoLBRXLB Pharmaceuticals Announces Presentation at the Piper Sandler 37th Annual Healthcare ConferenceGlobeNewswireNEW YORK, Nov. 24, 2025 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc ("LB Pharmaceuticals" or the "Company") (NASDAQ:LBRX) today announced that Heather Turner, Chief Executive Officer, will present at the Piper Sandler
- 1y agoLBRXLB Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireNEW YORK, Nov. 12, 2025 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc ("LB Pharmaceuticals" or the "Company") (NASDAQ:LBRX) today announced that it has granted to James Rawls, the new Senior Vice President of Regulatory
- 1y agoLBRXLB Pharmaceuticals Appoints Kaya Pai Panandiker as Chief Commercial OfficerGlobeNewswireNEW YORK, Nov. 12, 2025 (GLOBE NEWSWIRE) -- LB Pharmaceuticals, Inc ("LB Pharmaceuticals" or the "Company") (NASDAQ:LBRX), a clinical-stage biopharmaceutical company developing novel therapies for schizophrenia,
- 1y agoLBRXLB Pharmaceuticals Reports 3Q 2025 Financial Results and Recent Corporate UpdatesGlobeNewswireNEW YORK, Nov. 06, 2025 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc ("LB Pharmaceuticals" or the "Company") (NASDAQ:LBRX) today announced financial results for the third quarter ended on September 30, 2025 and provided
- 1y agoLBRXLB Pharmaceuticals Appoints James Rawls, Pharm.D., as Senior Vice President of Regulatory AffairsGlobeNewswireNEW YORK, Oct. 14, 2025 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc ("LB Pharmaceuticals" or the "Company") (NASDAQ:LBRX) today announced the appointment of James Rawls, Pharm.D., as Senior Vice President of Regulatory
- 1y agoLBRXLB Pharmaceuticals to Present Three Posters at 38th ECNP Congress Highlighting Clinical Activity and Safety Profile of LB-102 in Schizophrenia, Including Positive Effects on Cognition and Negative SymptomsGlobeNewswireNEW YORK, Oct. 06, 2025 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc ("LB Pharmaceuticals" or the "Company") (NASDAQ:LBRX) today announced that three posters featuring new and previously reported analyses from its Phase
- 1y agoLBRXLB Pharmaceuticals Strengthens Board of Directors with Appointments of William Kane and Rekha HemrajaniGlobeNewswireNEW YORK, Sept.
- 1y agoLBRXLB Pharmaceuticals Announces Pricing of its Upsized Initial Public OfferingGlobeNewswireNEW YORK, Sept. 10, 2025 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc ("LB Pharmaceuticals") today announced the pricing of its upsized initial public offering of 19,000,000 shares of its common stock at a public